 held on December 4th. The second session is scheduled for Saturday January 27th, 9:00-10:30 am at the Manchester Community Center. Resident participation is essential in developing future policy. Please join us. Your opinion is needed. We’ll be there to listen and discuss future options.
Not Again!I've been involved with married men for most of my adult life. I don't really believe one man and one woman can be together monogamously forever. With a married man, I don't feel smothered. But no matter how great it is, I always end up wanting more, which totally contradicts what I just said! I think I'm messed up in the head!
I think you don't love that man so much.
You're not messed up. I've been involved with a married man for the last five years and it is nice to know that there is someone out there that loves you and you can be with and feel good with, but that you don't have to wash his dirty underwear, but then again you find yourself asking, "Welllll, would it really be that bad to wash his dirty underwear?"
because you have been with a married man does not means you are messed up in the head, it could mean that you can't commit to a long term relationshipI find it hard to believe that your Wraith ships can cross the void in 3 days, while it takes 7 for most of our ships. Just seems off. But otherwise this is an amazing tech list and adds a little more immersion to the story.
Salut est ce que tu vas mettre les vaisseaux Oris? Par contre est ce que tu vas faire un cross over?
Thanks for explaining your ships in full detail. Some times it gets a little confusing. Also I thought Al'kesh had shields. In Stargate Continuum, Teal'c uses an Al'kesh's shields to protect a building that houses the second Stargate on Earth.
This is going to come in handily for the crossover!Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations

Background Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer predict dramatic clinical responses to tyrosine kinase inhibitor (TKI) treatment. The conclusion on EGFR mutation-specific antibodies by immunohistochemistry (IHC) is not consistent. We evaluated the clinical availability of EGFR mutation-specific antibodies, investigating the prediction role of mutant EGFRs and other IHC markers in TKI therapy in patients with advanced lung adenocarcinoma. Materials and methods We analyzed 637 primary lung adenocarcinomas from an unselected Chinese population. For IHC, antibodies against EGFR exon 19 E746_A750 deletions, exon 21 L858R mutations, thyroid transcription factor-1 (TTF-1), and Napsin-A were applied. Positivity was defined as staining score >0. Results Specificities of E746_A750 and L858R antibodies were 99.6% and 99.3%, while sensitivities were 86.0% and 82.7%, respectively. Tumors with Napsin-A positivity, TTF-1 positivity, EGFR mutations, and lepidic pattern showed a lower marker of proliferation index (Ki67). Higher expression scores of mutant EGFR protein, TTF-1 positivity, lower Ki67 proliferation index, and lepidic pattern were associated with longer progression-free survival. Conclusion High scores of mutant EGFR, Napsin-A positivity, TTF-1 positivity, lower Ki67 index, and lepidic pattern were favorable predictors for TKI therapy in patients with advanced lung adenocarcinoma.


Introduction
Lung cancer is the leading cause of death from cancer, in both males and females. 1 Non-small-cell lung cancer (NSCLC) accounts for ~85% of lung cancer cases. 2 In the last several decades, adenocarcinoma has become the predominant type of NSCLC. 3 Assessment of epidermal growth factor receptor (EGFR) mutations has become mandatory to choose the most active first-line treatment for patients with advanced primary lung adenocarcinoma. 4 Indeed, multiple clinical trials have demonstrated that first-line administration of an EGFR-tyrosine kinase inhibitor (EGFR-TKI) results in a prolonged progression-free survival (PFS) when compared with chemotherapy in patients carrying EGFR mutations. [5][6][7] However, a standardized test for the detection of EGFR mutations in NSCLC has not yet been approved. Amplification-refractory mutation system (ARMS) has been widely used in the People's Republic of China. However, this method is relatively expensive, time consuming, and not incorporated submit your manuscript | www.dovepress.com

356
Zhang et al in routine diagnostic procedures in many departments of pathology. In contrast, immunohistochemistry (IHC) has lower costs, shorter turnaround time, and is available in the majority of laboratories. For these reasons, mutation-specific antibodies might be a relevant alternative for determining EGFR status. So far, there have already been few reports on EGFR IHC in NSCLC, [8][9][10][11] although no consistent evaluation on IHC has been concluded.
Primary lung adenocarcinoma is a heterogeneous tumor with variations in the pathological profile. In 2011, a new histologic classification of lung adenocarcinoma was proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) to provide uniform terminology and diagnostic criteria for multidisciplinary strategic management. Several studies 12,13 have validated the correlation between adenocarcinoma subtypes based on IASLC/ATS/ERS classification and patient outcomes in respective cohorts. However, there have been few reports 14 on correlations between IASLC/ATS/ERS classification and clinical outcomes in patients receiving TKI drug therapy.
The aim of this study was to determine the sensitivity and specificity of mutation-specific antibodies in the detection of EGFR mutations in unselected Chinese patients with primary lung adenocarcinoma. Furthermore, to analyze the prognostic utility of lung adenocarcinoma IHC markers, including cytokeratin-7 (CK-7), TTF-1, and Napsin A, tumor cell proliferation index using a marker of the proliferation index (Ki67), the efficacy of mutant EGFR expression in EGFR-TKI treatment (using the current uniform cohort of advanced lung adenocarcinomas harboring EGFR mutations), and their association with IASLC/ATS/ERS classification were evaluated.

Materials and methods Patients
Details of 637 patients with primary lung adenocarcinoma from the archives in Cancer Center recorded from July 2011 to July 2014 were collected for this study. Clinicopathological variables, including age, sex, histologic type, and pathological stage were collected by reviewing the medical charts and pathology records. Patients were followed up from the date of pathology diagnosis until death or censored on December 31, 2014, which resulted in a follow-up period of 1-41 months (a median of 25 months). The study was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. As this was a retrospective study using archived tissue specimens, the Institutional Ethics Committee waived the need for written informed consent.

Tumor sample preparation
Tumor samples were fixed in 10% neutral buffered formalin and embedded in paraffin wax. The paraffin-embedded tumor tissue was sliced into 4 μm sections on microtomes for hematoxylin-eosin (H&E) staining, molecular tests, and IHC.
immunohistochemistry Two rabbit monoclonal antibodies specifically against EGFR with L858R point mutation in exon 21 (clone 43B2, catalog no 5354) or E746_A750 deletions in exon 19 (clone 6B6, catalog no 2085; Cell Signaling Technology, Danvers, MA, USA) were used for IHC. Other antibodies, including CK-7 (clone OV-TL 12/30, Maixin, Fuzhou, the People's Republic of China), Napsin-A (multiclone, Maixin), TTF-1 (clone 8G7G3/1, Maixin), Ki67 (clone MX006, Maixin), and anaplastic lymphoma kinase (ALK, clone D5F3; Cell Signaling Technology) were also employed. Sections of 4 μm thickness cut from formalin-fixed, paraffin-embedded tissue blocks were deparaffinized in xylene and rehydrated through a graded series of ethanol concentrations. The EGFR mutation-specific staining was scored based on membrane staining intensity as previously described: 15 0= no staining, 1+ = faint membranous staining in.10% of tumor cells, 2+ = moderate complete membranous staining in.10% of tumor cells, and 3+ = strong membranous staining in.10% of tumor cells. A positive immunoreactivity is defined as an IHC score $1+. Criteria for the interpretation of other immunostainings were as follows: distinct nuclear staining of.5% tumor cells defined as positive for TTF-1, and diffuse and intense cytoplasmatic staining of.50% tumor cells defined as positive for CK-7 and Napsin-A. The proliferation index of Ki67 was assessed based on the percentage of distinct nuclear staining in tumor cells.

357
Prediction role of immunohistochemistry markers for egFr-TKi therapy paraffin-embedded tissues were selected for the assay. Ten sections of 4 μm thick tumor tissue were cut and, if necessary, macrodissected in order to ensure high percentage of tumor cells. Tissue sections were treated once with xylene, followed by one wash in ethanol. The pellet was resuspended in tissue lysis buffer and treated with proteinase-K overnight at 56°C. After the inactivation of proteinase-K by heating, DNA was extracted. Then, the DNA sample was tested with a proprietary detection kit based on the principle of ARMS, according to the protocol of the EGFR Mutations Detection Kit (Amoy Diagnostics,